	Application No.	ı
INFORMATION DISCLOSURE	Filing Date	
STATEMENT BY APPLICANT &	First Named Inventor	
× × × × × × × × × × × × × × × × × × ×	Art Unit	
(Multiple sheets used when necessary) 1 1 2005	Examiner	

SHEET 1 OF 1

Application No. 10/644,277

Filing Date August 19, 2003

First Named Inventor Jean M. Gudas

Art Unit 1643

Examiner Parithosh K. Tungaturthi

Attorney Docket No. ABGENIX.091A

	U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>		
8.00		WO 02/02640	01/10/2002	Novartis AG				
					·			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
PLOS		Patent Abstracts of Japan. Vol. 1999, No.8 (1999). 11 06052, Teijin Ltd.	
		Patent Abstracts of Japan. Vol. 1997, No. 7 (1997). 09 067399, Mitsui Toatsu Chem. Inc.	
		Kaji et al. "Analysis of peptide motifs recognized with anti-MCP-1 monoclonal antibody." Peptide Science. 33-36 (1999).	
		Yoshimura et al. "Production and characterization of mouse monoclonal antibodies against human monocyte chemoattractant protein-1." Journal of Immunology. 147(7):2229-2233 (1991).	
-		Zhang et al. "Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1 mediated protein that inhibits MCP-1 mediated monocyte chemotaxis." <i>Journal of Biological Chemistry</i> . 269(22):15918-159924 (2003).	

1976870: 100605/CAP

	~ / \		
Examiner Signature	10/18 g	Date	Considered 11.0
*Evernines, Initial If as	forence considered	whother or not citation is in conformance	with MRED 600 Deput line through site is an

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T1 - Place a check mark in this area when an English language Translation is attached.

P E F96	M PT	O-1449 U.S. DEPARTMEN PATENT AND TR RMATION DISCLOSURE STATE BY APPLICANT	ADEMARK OFFIC	ATTY, DOCKET NO. ABGENIX.091A	APPLIC/ 10/644	ATION NO. ,277		SHEET 1
Eb (1.170	AKIK OCK	,,		APPLICANT Gudas et al.	· <b>-</b>			
ZENT & TRAD		SEVERAL SHEETS IF NECES	SARY)	FILING DATE August 19, 2003	. GROUP Not As	signed		
				U.S. PATENT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING	S DATE OPRIAT
				CORECU DATENY COCUMENTS				
EXAMINER			FOREIGN PATENT DOCUMENTS  COUNTRY	CLASS	SUBCLASS	TRANS	SLATION	
INITIAL				44-14-714-7-9-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-			YES	NC
POT	1.	WO 01/89565 A1	11/29/01	PCT				ļ
<del></del>	_	,						
	-		<del>                                     </del>					
EXAMINER INITIAL		01	HER DOCUMEN	ITS (INCLUDING AUTHOR, TITLE, DATE,	PERTINENT PAGES,	ETC.)		
POT	2.	PCT International Search	Report, Inte	rnational Application No. PCT/US	603/26232			
							<del></del>	
	_							
•					·			
					<del>-</del>			
:\DOCS\ET	A/E	TA-2351.DOC\090204\\vo						
					•			

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

DATE CONSIDERED

EXAMINER

				SHEET 1 0	F
	FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABGENIX.091A	APPLICATION NO. 10/644,277	
6	PE THEORMATION	DISCLOSURE STATEMENT			
1	1 0 2000 yel	Y APPLICANT	APPLICANT Gudas et al.		
1	( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )	L SHEETS IF NECESSARY)	FILING DATE August 19, 2003	GROUP Not Assigned	
/	A TRADEDAY				

. U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

	FOREIGN PATENT DOCUMENTS							
EXAMINER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL						YES	NO	
POA	1.	WO 01/89565	11/29/01					

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
PW	2.	Bradwell et al., "Control of hypercalcaemia of parathyroid carcinoma by immunisation," Lancet, 353: 370-373 (1999)
	3.	Hemmerich et al., "Identification of Residues in the Monocyte Chemotactic Protein-1 That Contact the MCP-1 Receptor, CCR2," Biochemistry, 38: 13013-13025 (1999)
	4.	Jarnagin et al., "Identification of Surface Residues of the Monocyte Chemotactic Protein 1 That Affect Signaling through the Receptor CCR2," <i>Biochemistry</i> , 38: 16167-16177 (1999)
	5.	Logue et al., "Production and characterisation of monoclonal antibodies to parathyroid hormone (1-34)," J. Immunol. Methods, 137: 159-166 (1991)
	6.	Magerlein et al., "Production of Sequence Specific Polyclonal Antibodies to Human Parathyroid Hormone 1-37 by Immunization with Multiple Antigenic Peptides," <i>Drug Res.</i> , 48: 783-787 (1998)
	7.	Vieira et al., "Monoclonal Antibodies to Bovine Parathyroid Hormone: Production and Characterization," Braz. J. Med. Biol. Res., 21: 1005-1011 (1988)
[ [	8.	Visser et al., "Production and Characterization of Antisera to Synthetic 1-34 Human Parathyroid Hormone Fragments: Possible Implications for the Correctness of Proposed Structures," <i>Acta Endocrinol.</i> , 90: 90-102 (1979)

S:\DOCS\SRG\SRG-1923.DOC\082803\Ivo

		<u> </u>	
EXAMINER	10 (	$\mathcal{N}$	DATE CONSIDERED 2/7/1
			DERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT